In vivoassessment of the metabolic activity of CYP2D6 diplotypes and alleles

Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization

(2014) J. Hicks et al.   CURRENT DRUG METABOLISM

Functional Characterization of Wild-type and 49 CYP2D6 Allelic Variants for N-Desmethyltamoxifen 4-Hydroxylation Activity

(2014) Yuka Muroi et al.   Drug Metabolism and Pharmacokinetics

Functional characterization of CYP2D6 enhancer polymorphisms

(2014) Danxin Wang et al.   HUMAN MOLECULAR GENETICS

Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novelCYP2D6*1haplotypes

(2014) Andrea Gaedigk et al.   PHARMACOGENOMICS

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

(2014) P Saladores et al.   PHARMACOGENOMICS JOURNAL

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

(2013) Wendy A. Teft et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

(2013) J K Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity

(2013) Danxin Wang et al.   HUMAN MOLECULAR GENETICS

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies

(2013) Kazuma Kiyotani et al.   JOURNAL OF HUMAN GENETICS

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

PharmGKB summary

(2013) Daniel J. Klein et al.   Pharmacogenetics and Genomics

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

(2012) M. P. Goetz et al.   CLINICAL CANCER RESEARCH

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Tamoxifen and CYP2D6: A Contradiction of Data

(2012) D. L. Hertz et al.   ONCOLOGIST

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

(2011) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

(2011) K R Crews et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan

(2010) K Abduljalil et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

(2010) Silvana Borges et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION